INCY News and Press, Incyte Corporation From 06/13/22

FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) As First and Only Systemic Medicine for Adults with Severe Alopecia Areata PR Newswire INDIANAPOLIS , June 13, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced t...

This portfolio strategy uses the quarterly 13F filings to extract 50 consensus stocks from 40 large hedge funds that have more than $3.5 billion Assets Under Management. From 1/2/2016 to date investing in all 50 stocks, equally weighted, would have produced a total return of 73.6%, an...

CTI BioPharma (NASDAQ:CTIC), a commercial-stage biotech focused on blood-related cancers, dropped ~9% in the pre-market Friday after the company disclosed data for its FDA-approved therapy pacritinib from patients with myelofibrosis and thrombocytopenia. The data from Phase 3 PERSIS...

AbbVie (NYSE:ABBV) said new data from a mid-stage trial suggest that eraly intervention in patients with myelofibrosis (MF) with navitoclax in combination with Incyte's (INCY) Jakafi led to improved outcomes. The company presented data from group 3 of a phase 2 trial, dubbed RE...

In the first quarter of 2022, Incyte Pharmaeuticals (INCY) reported a very strong quarterly results, highlighted by the solid launch of Opzelura, observes John McCamant, biotech sector specialist and editor of The Medical Technology Stock Letter. For further details see: McCamant's Insi...

Incyte (Nasdaq:INCY) today announced that multiple abstracts featuring data from its oncology portfolio will be presented at the upcoming European Hematology Association 2022 (EHA2022) Congress (June 9-17; virtual and in Vienna). “We are committed to advancing science that ca...

This portfolio strategy uses the quarterly 13F filings to extract 50 consensus stocks from 40 large hedge funds that have more than $3.5 billion Assets Under Management. After the Q1-2022 13F filings the consensus holdings were updated, 10 stocks were removed and 8 added from the univ...

A committee of the European Medicines Agency (EMA) recommended the approval of Eli Lilly (NYSE:LLY) and Incyte's (NASDAQ:INCY) Olumiant to treat adults with severe alopecia areata (AA). Olumiant is already approved in the EU to treat certain patients with rheumatoid arthritis, ...

CHMP Recommends Approval of Lilly and Incyte's OLUMIANT® (baricitinib) as the First and Only Centrally-Authorized Treatment for Adults with Severe Alopecia Areata (AA) PR Newswire INDIANAPOLIS , May 20, 2022 /PRNewswire/ -- Eli Lilly and Company (NYS...

Popularity isn't a guarantee of success in the stock market. Some well-known companies can be lousy investment choices while lesser-known ones can boast much more promising prospects. That's why it's worth looking past the hype to dig deeper and find stocks that may not be household names b...